Organigram And Rounding Out My Tax Loss Selling Basket (NASDAQ:OGI)

Tax Loss Selling Strategy

This is the final article regarding my tax loss selling basket. I explained portions of the rationale for the strategy in the first three articles (here, here & here).

However, for those who haven’t read the earlier articles, here’s a quick synopsis:

• Investors who have net realized capital gains in the year can offset these by selling losers before December 30th (I previously had said tax treatment is by settlement date, but it’s actually by trade date for long positions).
• Stocks that are down on the year and preferably at multi year lows are good candidates for such selling.
• Because of the year-end deadline, investors who sell can become quite indiscriminate and this can create quick price plunges.
• Wash sale rules mean any investor who might want to get back into these names after realizing losses must wait 30 days. For this reason, I give the strategy through the middle of March to work, and no matter what the results, I sell the stock by that date. (If the stock bounces before then, I try to scale out of my position.)

Today I’m going discuss the last full position in the basket, viz. Organigram (NASDAQ:OGI)(TSX:OGI:CA) and then finish the article by tabulating the full list including entries that I haven’t written individual articles about.

As can be seen by the 5 year chart, every OGI shareholder is sitting on a loss, and for some of them the loss may be in the neighborhood of 70% to 90%. Thus there are many potential tax loss sellers in this name.

And as seen in the six month chart, there was a big dip at the end of December which could very well have been tax loss sellers throwing in the towel on this name. My buys for the basket were done during this latter period.

Organigram

Organigram is a licensed Canadian marijuana producer & wholesaler with a number of well known brands in the recreational and medical marijuana spaces. It also has a small international presence in Israel and Australia.

It has grown revenues but at the cost of increasing cash flow losses.

The company expects to improve margins in 2023, but there’s no predictions of profitability.

Valuation

As the stock has been beaten down, it now sports relatively decent valuation numbers, in particular on EV/sales and Price to Book ratios.

Cash on Hand

As of August 31, 2022, OGI had $68.5M (Canadian) in cash and $30M in short term investments. The company has about 314M shares outstanding, so that means it has cash and short term investments of $0.31 Canadian per share, or $0.23 US per share. That’s a little bit more than a quarter of the share price held in cash and short term investments.

OGI’s cash position also makes it less likely that the company will have to engage in a dilutive financing within my contemplated holding period (less than three months).

Quant Rating

Seeking Alpha has a hold rating on OGI, with all factor grades confirming it. For this reason I’m not considering holding the stock outside of my pre-planned window.

Risks

OGI has been a chronically money losing operation though it is growing revenues. Unless it can drastically improve margins, it risks eventually going bankrupt.

However in the short term it has sufficient cash to avoid near term financing, which slightly reduces the risk here.

Trading Strategy

I have taken a full position in OGI with the hopes of scaling out if the stock price recovers from its presumed tax loss selling swoon. Either way I will be out of the stock by mid March.

Tax Loss Selling Basket

I haven’t been able to write up all of the entries in my tax loss selling basket, but here is a tabulated summary of the positions. Note that this year I decided to space out my buys in two halves, so in some cases I only have half a position; in others I have a full position.

Company / Symbol	Position Size	Status
Achilles Therapeutics (ACHL)	Full	Open
AC Immune (ACIU)	Full	Open
ASLAN Pharmaceuticals (ASLN)	Half	Open
BlackSky Technology (BKSY)	Half	Open
Chimerix (CMRX)	Half	Open
DBV Technologies (DBVT)	Full	Sold ~25% of initial position
HCW Biologics (HCWB)	Half	Open
InflaRx (IFRX)	Half	Sold entire position
Isoray (ISR)	Full	Open
Kandi Technologies (KNDI)	Half	Open
23andMe (ME)	Full	Open
Organigram (OGI)	Full	Open
Sesen Bio (SESN)	Half	Open
Trevi Therapeutics (TRVI)	Half	Open

Click to enlarge

Editor’s Note: This article covers one or more microcap stocks. Please be aware of the risks associated with these stocks.